Renamed Atterx Biotherapeutics in late 2014/early 2015, , ConjuGon (now Atterx) has been working on development of fundamentally new therapeutics to combat the growing epidemic of antibioticresistant bacterial infections. Antibiotic resistance is a medical crisis, globally responsible for hundreds of thousands of deaths each year. The firm's core technology is a new way to kill unwanted and even multi-drug resistant bacteria. In the product piepline are 2 drugs, one to combat catheter-associated urinary tract infections (CAUTIs), and another to treat resistant infections of large wounds caused by Gram negative bacteria
